Redeye briefly comments on Cinclus’ announcement that the first patient has been dosed in its pivotal phase III study with linaprazan glurat...
Redeye comments on Cinclus’ announcement that the first patient has been screened in its pivotal Phase III study with linaprazan glurate in ...
Redeye leaves a comment following Cinclus’ announcement earlier today of having initiated its phase III HEEALING 1 study in severe erosive G...
Redeye provides a research update following the Q2 report published by Cinclus earlier today.
Redeye comments on Phathom Pharmaceuticals’ recent announcement that the FDA has approved its Citizen Petition, confirming extended market e...
Redeye comments on Cinclus Pharma’s announcement earlier today of a EUR220m licensing agreement with leading European pharmaceutical company...
Redeye provides a research update following the Q1 report published by Cinclus earlier today.
Redeye comments on the Q4 report recently published by Cinclus Pharma’s peer, Phathom Pharmaceuticals.
Redeye provides a research update following the Q4 report published by Cinclus earlier today.
Redeye leaves a comment following Cinclus’ announcement of linaprazan glurate having received market approval in China.
Redeye provides a research update following the Q3 report published by Cinclus earlier today.
Redeye leaves a comment following Cinclus’ recent announcement that it has agreed on Paediatric Investigation Plan (PIP) with EMA.
Redeye leaves a short comment following Cinclus’ recent announcement that the manufacturing of the Investigational Medicinal Product (IMP), ...
Redeye initiates coverage of Cinclus Pharma, a Swedish biotech company offering a next-generation solution to the USD+5bn GERD treatment mar...
